Copyright
©The Author(s) 2024.
World J Gastroenterol. Apr 7, 2024; 30(13): 1780-1790
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1780
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1780
Clinical trial number | Treatment | Stage | Country |
NCT05185947 | Paclitaxel + nilotinib | Phase II | United States |
NCT04731467 | Nivolumab, Nab-paclitaxel, gemcitabine | Phase I/II | United States, Spain |
NCT03129139 | Minnelide™ + protein-bound paclitaxel | Phase I | United States |
NCT05453825 | Navicixizumab + paclitaxel or irinotecan | Phase II | United States |
NCT05107674 | NX-1607 (+ paclitaxel) | Phase Ia/b | United States, United Kingdom |
NCT03678883 | 9-ING-41, gemcitabine, doxorubicin, carboplatin, Nab-paclitaxel, paclitaxel, irinotecan | Phase II | United States, Belgium, Canada, France, Netherlands, Portugal, Spain |
NCT05395910 | Paclitaxel | Phase I | Singapore (note: Peritoneal carcinomatosis) |
NCT04666688 | LYT-200, tislelizumab, gemcitabine + Nab-paclitaxel | Phase I/II | United States |
NCT04444921 | Carboplatin, nivolumab, paclitaxel | Phase III | United States (note: Anal cancer) |
NCT04083599 | GEN1042, pembrolizumab, cisplatin, carboplatin, 5-FU, gemcitabine, Nab-paclitaxel, pemetrexed, paclitaxel | Phase I/II | United States, Denmark, France, Georgia, Germany, Israel, Italy, Republic of Korea, Republic of Moldova, Spain, Taiwan, United Kingdom |
NCT03872947 | TRK-950, irinotecan, leucovorin, 5-FU, gemcitabine, cisplatin, carboplatin, ramucirumab, paclitaxel, nivlumab, pembrolizumab, imiquimod cream, bevacizumab, topotecan, PCD | Phase I | United States, France |
NCT04644068 | ADZ5305, paclitaxel, carboplatin, T-Dxd, Dato-DXd, camizestrant | Phase I/II | United States, Australia, Canada, China, Czechia, Hungary, Italy, Japan, Republic of Korea, Poland, Russian Federation, Spain, United Kingdom |
NCT06047379 | NEO212, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, FOLFIRI, bevacizumab | Phase I/II | United States |
Clinical trial number | Treatment | Stage | Country |
NCT04553692 | IGM-844 + FOLFIRI (+ bevacizumab) (docetaxel included as a part) | Phase I | United States |
NCT04256707 | Selinexor, docetaxel, pembrolizumab, FOLFIRI | Phase I/II | Israel |
NCT02817633 | TSR-022, nivolumab, TSR-042, 033, docetaxel, pemetrexed, cisplatin, carboplatin | Phase I | United States |
NCT05714553 | Fosifloxuridine nafalbenamide, leucovorin, pembrolizumab, docetaxel | Phase I/II | United Kingdom |
NCT04895709 | BMS-986340, 936558-01, docetaxel | Phase I/II | United States |
NCT04894370 | (Sample collection) | Phase II | France |
Clinical trial number | Conditions | Trial stage | Enrollment | Study period |
NCT01570790 | Age-related macular degeneration | Phase I/II | 8 | 2003-2005 |
NCT01423149 | Myopia | Phase II | 23 | 2005-2007 |
NCT00060242 | Head and neck cancer | Phase II | 26 | 2003-2008 |
NCT00113438 | Cancer (non-specified) | Phase II | 23 | 2005-2007 |
NCT00960557 | Neoplasm metastasis | Phase I | 16 | 2009-2010 |
NCT00077103 | Head and neck cancer | Phase I/II | 4 | 2003-2007 (terminated) |
NCT00003768 | Adult solid tumor (unspecified) | Phase I | 25 | 1998-2001 |
NCT00507429 | Anaplastic thyroid cancer | Phase II/III | 80 | 2007-2011 (terminated) |
NCT01023295 | Polypoidal choroidal vasculopathy | Phase II | 20 | 2009-2010 |
NCT00395434 | Tumors (unspecified) | Phase I | 20 | 2006-2007 |
NCT02576301 | Acute myelogenous leukemia/myelodysplastic syndromes | Phase I/II | 105 | 2015-2020 (status unknown) |
NCT00003698 | Adult solid tumor (unspecified) | Phase I | 35 | 1998-2003 |
NCT01085656 | Acute myelogenous leukemia/myelodysplastic syndromes | Phase I | 18 | 2011-2016 (terminated) |
NCT02279602 | Neuroendocrine tumors | Phase II | 7 | 2014-2016 |
NCT00699517 | Sarcoma | Phase III | 355 | 2008-2013 |
NCT02132468 | Neuroendocrine tumors | Phase II | 18 | 2014-2016 |
NCT01701349 | Anaplastic thyroid cancer | Phase III | 0 | 2015-2017 (withdrawn) |
NCT00653939 | Non-small cell lung cancer | Phase II | 63 | 2008-2011 |
NCT02641639 | Platinum-resistant ovarian cancer | Phase II/III | 91 | 2016-2017 (terminated) |
NCT01240590 | Anaplastic thyroid cancer | Phase I/II | 27 | 2011-2016 |
- Citation: Kita K, Burdowski A. Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management. World J Gastroenterol 2024; 30(13): 1780-1790
- URL: https://www.wjgnet.com/1007-9327/full/v30/i13/1780.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i13.1780